Patrys’s antibody written up in melanoma journal

A peer-reviewed article exploring the development of Patrys’s (ASX:PAB) anticancer antibody PAT-SM6 supports its potential in killing melanoma cells.

The article, published in Melanoma Research, provides a summary of the pre-clinical and early-clinical development of the lgM antibody, noting that PAT-SM6 is the only therapeutic under development which specifically targets the cancer-specific isoform of GRP78.

The antibody also binds to low-density lipoprotein, and lab research suggests it is more effective in the presence of both targets.

The article details data suggesting that the antibody can trigger cell death in cancer cells, along with the results of an early clinical trial which show that even at microdose levels, PAT-SM6 was present in tumour biopsies.

Also included are data from animal trials showing that PAT-SM6 eliminated the development of metastasised tumours in mice, and was safe and well tolerated in monkey toxicology studies.

It concludes that the available data “justify the move forward to larger multidose trials in patients with melanoma and other PAT-SM6-expressing tumours”.

Patrys is separately in clinical trials for PAT-SM6 in multiple myeloma.

The company is also developing another anticancer antibody candidate, PAT-LM1, and last week announced it had secured a New Zealand patent covering the use of this antibody to bind to target gene protein Nmt55/NONO to treat tumour metastasis.

This marks the second jurisdiction for which Patrys has received patent protection for PAT-LM1 after the US.

Patrys shares were trading 6.45% lower at $0.029 as of around 1.30 pm on Wednesday.